CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 615 enrolled
Drug / intervention
Mirapex LAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01525641
NCT01525641N/ACompleted
CompareCT.gov

Special Survey on Long-term Drug Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

Boehringer Ingelheim·observational·Posted Feb 3, 2012·Updated Aug 14, 2015

In Brief

An observational study evaluating Mirapex LA for Parkinson Disease. Completed, enrolled 615 participants across 118 sites.

Detailed Summary

Post-marketing surveillance (PMS) to investigate the safety and efficacy of long-term daily use of Mirapex®-LA Tablets in patients with Parkinson's disease.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2012
Enrollment StartFeb 1, 2012
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.4 years ago

Interventions

Mirapex LAdrug

Pramipexole Hydrochloride Hydrate